Jump to Main Content
- Johnson, Nia R., et al. Show all 14 Authors
- Colloids and surfaces 2016 v.144 pp. 8-20
- antibodies; antigens; apoptosis; colloids; iron oxides; nanoparticles; particle size; pro-apoptotic proteins; prostatic neoplasms; proteins; zeta potential
- ... Docetaxel (Dtxl) is currently the most common therapeutic option for prostate cancer (PC). However, adverse side effects and problems associated with chemo-resistance limit its therapeutic outcome in clinical settings. A targeted nanoparticle system to improve its delivery to and activity at the tumor site could be an attractive strategy for PC therapy. Therefore, the objective of this study was t ...
- PubMed Central: